December 18 2017
On November 1 2017 the Federal Court of Appeal heard Alexion's appeal of a decision striking out its constitutional challenge to the price regulation scheme and confiscatory powers found in Sections 83 to 86 and 87(1) of the Patent Act.(1) A decision is under reserve.
Alexion also has a pending judicial review of the Patented Medicine Prices Review Board's decision that it sold Soliris (eculizumab) at excessive prices (for further details please see "Patented Medicine Prices Review Board update").
For further information on this topic please contact Urszula Wojtyra at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
(1) Further information is available here.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.